H Lyu1,2, K Yoshida3, S K Tedeschi4, S Zhao4,5, C Xu4, S U Nigwekar6, B Z Leder7, D H Solomon8,9. 1. Department of Medicine, Harvard Medical School, Boston, MA, USA. 2. Department of Orthopedics, Chinese PLA General Hospital, Beijing, China. 3. Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 4. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA. 5. Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. 6. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 7. Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 8. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA. dhsolomon@partners.org. 9. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. dhsolomon@partners.org.
Abstract
Intervals between dual-energy X-ray absorptiometry (DXA) scans were evaluated in a large cohort of typical clinical practice. Intensive DXA scanning (intervals < 23 months) decreased substantially, from 16.7% in 2006 to 6.7% in 2015. INTRODUCTION: Serial dual-energy X-ray absorptiometry (DXA) measurements are suggested for patients at high risk of fractures. However, little is known about how often DXA testing occurs in clinical practice. METHODS: We examined time intervals between DXA testing for monitoring purpose at two academic medical centers in the US between 2004 and 2017. The primary outcome was the presence of testing intervals < 23 months (termed "intensive DXA testing"). A generalized linear mixed model was used to evaluate the association between selected patient-level clinical factors and intensive DXA testing. RESULTS: Forty-nine thousand four hundred ninety-four DXA tests from 20,200 patients were analyzed. The mean time interval between scans was 36 ± 21 months. Only 11.1% of the repeated DXA testing met the criterion for intensive testing. The percentage of intensive DXA testing dropped from 16.7% in 2006 to 6.7% in 2015 (p for trend < 0.001). After adjusting for age, gender, number of outpatient visits, and calendar year, correlates of intensive DXA testing included a baseline T-score < -2.5 at any anatomic site (OR, 4.8; 95%CI, 4.0-5.7), active use of drugs for osteoporosis (OR, 1.6; 95%CI, 1.3-1.9), and active use of glucocorticoids (OR, 1.3; 95%CI, 1.2-1.4). CONCLUSIONS: The predictors of intensive DXA testing suggest that this practice is used preferentially in patients with multiple risk factors and to monitor the response to pharmacotherapy. However, intensive DXA testing has become less common in real-world clinical practice over the last decade. Further studies are required to better define the optimal use of bone mineral density testing in this vulnerable population.
Intervals between dual-energy X-ray absorptiometry (DXA) scans were evaluated in a large cohort of typical clinical practice. Intensive DXA scanning (intervals < 23 months) decreased substantially, from 16.7% in 2006 to 6.7% in 2015. INTRODUCTION: Serial dual-energy X-ray absorptiometry (DXA) measurements are suggested for patients at high risk of fractures. However, little is known about how often DXA testing occurs in clinical practice. METHODS: We examined time intervals between DXA testing for monitoring purpose at two academic medical centers in the US between 2004 and 2017. The primary outcome was the presence of testing intervals < 23 months (termed "intensive DXA testing"). A generalized linear mixed model was used to evaluate the association between selected patient-level clinical factors and intensive DXA testing. RESULTS: Forty-nine thousand four hundred ninety-four DXA tests from 20,200 patients were analyzed. The mean time interval between scans was 36 ± 21 months. Only 11.1% of the repeated DXA testing met the criterion for intensive testing. The percentage of intensive DXA testing dropped from 16.7% in 2006 to 6.7% in 2015 (p for trend < 0.001). After adjusting for age, gender, number of outpatient visits, and calendar year, correlates of intensive DXA testing included a baseline T-score < -2.5 at any anatomic site (OR, 4.8; 95%CI, 4.0-5.7), active use of drugs for osteoporosis (OR, 1.6; 95%CI, 1.3-1.9), and active use of glucocorticoids (OR, 1.3; 95%CI, 1.2-1.4). CONCLUSIONS: The predictors of intensive DXA testing suggest that this practice is used preferentially in patients with multiple risk factors and to monitor the response to pharmacotherapy. However, intensive DXA testing has become less common in real-world clinical practice over the last decade. Further studies are required to better define the optimal use of bone mineral density testing in this vulnerable population.
Entities:
Keywords:
Dual-energy X-ray absorptiometry; Osteoporosis; Repeated scan; Short interval
Authors: Jie Zhang; Elizabeth Delzell; Hong Zhao; Andrew J Laster; Kenneth G Saag; Meredith L Kilgore; Michael A Morrisey; Nicole C Wright; Huifeng Yun; Jeffrey R Curtis Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: A M Schott; C Ganne; D Hans; G Monnier; R Gauchoux; M A Krieg; P D Delmas; P J Meunier; C Colin Journal: Osteoporos Int Date: 2006-10-13 Impact factor: 4.507
Authors: Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger Journal: Am J Med Date: 2003-08-15 Impact factor: 4.965
Authors: Daniel H Solomon; Stephen S Johnston; Natalie N Boytsov; Donna McMorrow; Joseph M Lane; Kelly D Krohn Journal: J Bone Miner Res Date: 2014-09 Impact factor: 6.741